Schrodinger Inc (SDGR)
Receivables turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|
Revenue | US$ in thousands | 216,666 | 180,955 | 137,931 | 108,095 |
Receivables | US$ in thousands | 65,992 | 55,953 | 31,744 | 31,423 |
Receivables turnover | 3.28 | 3.23 | 4.35 | 3.44 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $216,666K ÷ $65,992K
= 3.28
The trend in Schrodinger Inc's receivables turnover over the past five years shows a general decline, moving from 3.32 in 2019 to 2.43 in 2023. This indicates that the company is taking longer to collect its accounts receivable compared to previous years. A lower receivables turnover ratio could suggest potential issues with credit policies, collection efficiency, or the quality of customers. Further investigation into the reasons behind the decreasing trend in receivables turnover is warranted to assess the impact on the company's overall liquidity and cash flow management.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
Schrodinger Inc
SDGR
3.28
Abbott Laboratories
ABT
6.01
AbbVie Inc
ABBV
4.87
Alkermes Plc
ALKS
4.93
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.75
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44